Axogen Inc (AXGN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Axogen Inc (AXGN) has a cash flow conversion efficiency ratio of 0.027x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($3.22 Million) by net assets ($120.81 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Axogen Inc - Cash Flow Conversion Efficiency Trend (1989–2024)
This chart illustrates how Axogen Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read AXGN current and long-term liabilities for a breakdown of total debt and financial obligations.
Axogen Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Axogen Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hyundai Energy Solutions Co Ltd
KO:322000
|
0.073x |
|
Mayr-Melnhof Karton AG
VI:MMK
|
0.011x |
|
Dynapack International Technology
TWO:3211
|
0.049x |
|
North West Company Inc
TO:NWC
|
0.059x |
|
Frontken Corporation Bhd
KLSE:0128
|
0.095x |
|
Sunstone Hotel Investors Inc
NYSE:SHO
|
0.028x |
|
Zydus Wellness Limited
NSE:ZYDUSWELL
|
0.070x |
|
Jamf Holding
NASDAQ:JAMF
|
0.083x |
Annual Cash Flow Conversion Efficiency for Axogen Inc (1989–2024)
The table below shows the annual cash flow conversion efficiency of Axogen Inc from 1989 to 2024. For the full company profile with market capitalisation and key ratios, see Axogen Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $103.91 Million | $4.54 Million | 0.044x | +173.05% |
| 2023-12-31 | $95.67 Million | $-5.72 Million | -0.060x | +62.44% |
| 2022-12-31 | $101.00 Million | $-16.07 Million | -0.159x | -33.56% |
| 2021-12-31 | $112.55 Million | $-13.40 Million | -0.119x | -52.37% |
| 2020-12-31 | $123.15 Million | $-9.63 Million | -0.078x | +48.02% |
| 2019-12-31 | $132.15 Million | $-19.87 Million | -0.150x | -23.74% |
| 2018-12-31 | $146.98 Million | $-17.86 Million | -0.122x | +66.87% |
| 2017-12-31 | $25.18 Million | $-9.24 Million | -0.367x | +51.15% |
| 2016-12-31 | $14.92 Million | $-11.20 Million | -0.751x | +52.85% |
| 2015-12-31 | $8.20 Million | $-13.05 Million | -1.593x | -271.36% |
| 2014-12-31 | $-11.25 Million | $-10.45 Million | 0.929x | +101.22% |
| 2013-12-31 | $136.63K | $-10.44 Million | -76.444x | -2597.08% |
| 2012-12-31 | $-2.83 Million | $-8.66 Million | 3.061x | +362.55% |
| 2011-12-31 | $6.07 Million | $-7.08 Million | -1.166x | -381.30% |
| 2010-12-31 | $10.03 Million | $-2.43 Million | -0.242x | -117.35% |
| 2009-12-31 | $11.06 Million | $15.44 Million | 1.396x | +192.99% |
| 2008-12-31 | $313.19K | $-470.16K | -1.501x | -188.97% |
| 2007-12-31 | $898.82K | $-466.95K | -0.520x | -2239.79% |
| 2006-12-31 | $1.30 Million | $-28.79K | -0.022x | +94.79% |
| 2005-12-31 | $1.66 Million | $-709.62K | -0.426x | -210.74% |
| 2004-12-31 | $2.28 Million | $878.84K | 0.385x | +116.91% |
| 2003-12-31 | $-153.77K | $-27.30K | 0.178x | +122.73% |
| 2002-12-31 | $966.80K | $-755.02K | -0.781x | +5.42% |
| 2001-12-31 | $3.54 Million | $-2.92 Million | -0.826x | -206.41% |
| 2000-12-31 | $4.72 Million | $-1.27 Million | -0.269x | -721.89% |
| 1999-12-31 | $6.10 Million | $-200.00K | -0.033x | -118.36% |
| 1998-12-31 | $8.40 Million | $1.50 Million | 0.179x | +1471.43% |
| 1997-12-31 | $8.80 Million | $100.00K | 0.011x | -38.07% |
| 1996-12-31 | $10.90 Million | $200.00K | 0.018x | +105.50% |
| 1995-12-31 | $11.20 Million | $100.00K | 0.009x | 0.00% |
| 1994-12-31 | $11.20 Million | $100.00K | 0.009x | -67.26% |
| 1993-12-31 | $11.00 Million | $300.00K | 0.027x | -79.94% |
| 1992-12-31 | $10.30 Million | $1.40 Million | 0.136x | +19.86% |
| 1991-12-31 | $9.70 Million | $1.10 Million | 0.113x | -23.24% |
| 1990-12-31 | $8.80 Million | $1.30 Million | 0.148x | +69.89% |
| 1989-12-31 | $6.90 Million | $600.00K | 0.087x | -- |
About Axogen Inc
Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porc… Read more